Motley Fool Money A New Name in Weight-Loss Drugs
May 20, 2024
Asit Sharma, a Motley Fool analyst, dives into the weight-loss drug landscape with Hims & Hers launching affordable GLP-1 injections, taking on giants Novo Nordisk and Eli Lilly. He discusses the changing dynamics in the market, and a surprising company thriving in this space. The conversation also covers Wix's impressive pivot to an AI-driven, cash flow-focused model, highlighting its innovative website builder. Plus, hear insights on the fitness industry as gym franchises face challenges amidst a shakeup in consumer trends.
AI Snips
Chapters
Transcript
Episode notes
Hims & Hers Enters Weight Loss Market
- Hims & Hers is expanding into the weight loss market by offering compounded GLP-1 injections.
- This follows their established model of providing cheaper, accessible versions of popular medications.
Compound GLP-1s: A Cheaper Alternative
- Hims & Hers offers compounded GLP-1 injections, similar to Ozempic or Mounjaro, but at a lower price.
- Their weight loss program subscriptions will start at $199 per month.
Invest in Weight Loss Wholesalers
- Consider investing in companies like AmerisourceBergen that benefit from the entire weight loss trend.
- Wholesalers profit regardless of specific drug approvals, reducing investment risk.